We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


European Medicines Agency Approves Orphan Medicinal Product Application of DCPrime's AML Vaccine

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "European Medicines Agency Approves Orphan Medicinal Product Application of DCPrime's AML Vaccine"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

DCPrime has announced that the Committee for Orphan Medical Products (COMP) of the European Medicines Agency has issued a positive opinion recommending DCPrime’s application for orphan drug designation of, the company’s dendritic cell-based cancer vaccine candidate, which targets Acute Myeloid Leukemia (AML).

"This orphan drug designation is a major step in DCPrime’s work towards approval of our AML vaccine, and clearly reflects the COMP’s view of the potential of this vaccine in improving survival of patients with AML”, said DCPrime’s CEO and CSO Dr. Ada Kruisbeek.

Kruisbeek continued, "At the present time, AML patients lack an approved therapy to prevent the cancer from returning after standard chemotherapy. In 75% of the patients treated, the leukemia returns within 2 years. Our vaccine is intended as a therapy to prevent the cancer from coming back, and in our current clinical study we are establishing if we can delay or prevent AML from returning. If we succeed, this will improve survival outcomes in AML.”